1
|
Ramsey SD, Bansal A, Li L, O'Donnell PV, Fuchs EJ, Brunstein CG, Eapen M, Thao V, Roth JA, Steuten L. Cost-Effectiveness of Unrelated Umbilical Cord Blood vs. HLA Haploidentical Related Bone Marrow Transplant: Evidence from BMT CTN 1101. Transplant Cell Ther 2023:S2666-6367(23)01257-5. [PMID: 37120135 DOI: 10.1016/j.jtct.2023.04.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/06/2023] [Accepted: 04/24/2023] [Indexed: 05/01/2023]
Abstract
BACKGROUND BMT CTN 1101 was a Phase III randomized controlled trial comparing reduced intensity conditioning followed by double unrelated umbilical cord blood (UCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) transplantation for patients with high-risk hematologic malignancies. OBJECTIVE The objective of this study is to report the results of a parallel cost-effectiveness analysis. STUDY DESIGN Three hundred sixty-eight patients were randomized to unrelated UCB (n=186) or haplo-BM (n=182) transplant. We estimated healthcare utilization and costs using propensity score-matched BMT patients from the OptumLabsⓇ Data Warehouse for trial participants <65 years and Medicare claims for participants ≥65 years. Weibull models were used to estimate 20-year survival. EQ-5D surveys by trial participants were used estimate Quality-Adjusted Life Years (QALYs). RESULTS At 5-year follow-up, survival was 42% for haplo-BM versus 36% for UCB (P=.06). Over a 20-year time horizon, haplo-BM is expected to be more effective (+0.63 QALY) and more costly +$118,953) for persons under 65. For those over 65, haplo-BM is expected to be more effective and less costly. In one-way uncertainty analyses, for persons <65, the cost per QALY result was most sensitive to life years and health state utilities. For persons ≥65, life years were more influential than costs and health state utilities. CONCLUSION Compared to UCB, haplo-BM was moderately cost-effective for patients aged <65 years, and less costly and more effective for persons ≥65 years. Haplo-BM is a fair value choice for commercially insured patients with high-risk leukemia and lymphoma who require HCT. For Medicare enrollees, haplo-BM is a preferred choice when considering costs and outcomes.
Collapse
Affiliation(s)
- S D Ramsey
- Fred Hutchinson Cancer Center, Seattle, WA; University of Washington, Seattle, WA.
| | - A Bansal
- Fred Hutchinson Cancer Center, Seattle, WA; University of Washington, Seattle, WA
| | - L Li
- Fred Hutchinson Cancer Center, Seattle, WA
| | - P V O'Donnell
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - E J Fuchs
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
| | - C G Brunstein
- Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
| | - M Eapen
- Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
| | - V Thao
- Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; OptumLabs, Edina, MN
| | - J A Roth
- University of Washington, Seattle, WA; Pfizer, New York, NY
| | - Lmg Steuten
- Office of Health Economics, London, United Kingdom
| |
Collapse
|
2
|
Hershman DL, Till C, Wright JD, Ramsey SD, Barlow WE, Unger JM. Abstract P6-12-09: Association between cardiovascular risk factors and cardiac events among breast cancer patients enrolled in SWOG clinical trials. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-12-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Due to early detection and improved treatments, women with breast cancer are living longer. Breast cancer shares risk factors with cardiovascular disease (CVD), and its treatments have adverse cardiovascular effects. Less is known about the association between cardiac risk factors and long-term cardiac events among the patients enrolled in breast cancer trials, as most trials fail to collect this information.
Methods: We examined the SWOG database to identify phase II/III breast cancer trials from 1999-2011. Among patients over 65 years, we linked the SWOG clinical records to Medicare claims data according to social security number and date of birth. This analysis included patients with 6+ months of Medicare coverage prior to baseline and 12+ months of Medicare coverage at any point after baseline. The comorbidities investigated at baseline were diabetes, hypertension, hypercholesterolemia, coronary artery/ischemic heart disease and obesity. A cardiac event was defined as an acute ischemic event or acute heart failure. Cox regression was used to calculate time-to-event, stratified by study ID and adjusted for baseline age, race, and prognostic risk score. Cox regression was performed separately for each CVD risk factor, and an additional analysis was performed to assess the impact of having multiple concurrent risk factors. Secondary analyses were performed separately by study type (Adjuvant, Advanced).
Results: Among patients linked to Medicare included in this cohort (N=742), the median age was 70, and median follow-up was 6 years. The majority of patients were non-Hispanic white. The most prevalent conditions were hypercholesterolemia (58%) and hypertension (73%). Only 13% had no baseline risk CVD factors. In a Cox regression, all baseline risk factors except hypercholesterolemia and obesity were statistically significantly or borderline statistically significantly associated with an increased risk of eventual cardiac event, and for ischemic heart disease the increased risk was more than two-fold (HR=2.27, 95% CI=1.46-3.54, p=0.0003) and for baseline diabetes nearly two-fold (HR=1.75, 95% CI=1.13-2.71, p=0.01). In addition, there was evidence of a linear association of number of concurrent risk factors and cardiac events (HR per additional risk factor = 1.35 (1.09-1.66), p=0.005). In the stratified analysis, the associations were statistically significant only for participants on adjuvant studies. No association between baseline cardiac risk factors and cardiovascular outcomes were seen among patients with advanced cancer.
Conclusions:In summary, we found that even among healthy breast cancer patients selected for clinical trials, baseline CVD risk factors are associated with an increased risk of cardiac events, however this association was not observed for patients with advanced disease, who are more likely to die from breast cancer before experiencing a cardiovascular event.
Citation Format: Hershman DL, Till C, Wright JD, Ramsey SD, Barlow WE, Unger JM. Association between cardiovascular risk factors and cardiac events among breast cancer patients enrolled in SWOG clinical trials [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-12-09.
Collapse
Affiliation(s)
- DL Hershman
- Columbia University Medical Center, New York, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistical Center, Seattle, WA
| | - C Till
- Columbia University Medical Center, New York, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistical Center, Seattle, WA
| | - JD Wright
- Columbia University Medical Center, New York, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistical Center, Seattle, WA
| | - SD Ramsey
- Columbia University Medical Center, New York, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistical Center, Seattle, WA
| | - WE Barlow
- Columbia University Medical Center, New York, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistical Center, Seattle, WA
| | - JM Unger
- Columbia University Medical Center, New York, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistical Center, Seattle, WA
| |
Collapse
|
3
|
Molvig K, Schmitt MJ, Albright BJ, Dodd ES, Hoffman NM, McCall GH, Ramsey SD. Low Fuel Convergence Path to Direct-Drive Fusion Ignition. Phys Rev Lett 2016; 116:255003. [PMID: 27391731 DOI: 10.1103/physrevlett.116.255003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Indexed: 06/06/2023]
Abstract
A new class of inertial fusion capsules is presented that combines multishell targets with laser direct drive at low intensity (2.8×10^{14} W/cm^{2}) to achieve robust ignition. The targets consist of three concentric, heavy, metal shells, enclosing a volume of tens of μg of liquid deuterium-tritium fuel. Ignition is designed to occur well "upstream" from stagnation, with minimal pusher deceleration to mitigate interface Rayleigh-Taylor growth. Laser intensities below thresholds for laser plasma instability and cross beam energy transfer facilitate high hydrodynamic efficiency (∼10%).
Collapse
Affiliation(s)
- Kim Molvig
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Mark J Schmitt
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - B J Albright
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - E S Dodd
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - N M Hoffman
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - G H McCall
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S D Ramsey
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| |
Collapse
|
4
|
Ramsey SD, McCune JS, Blough DK, McDermott CL, Beck SJ, López JA, Deeg HJ. Patterns of blood product use among patients with myelodysplastic syndrome. Vox Sang 2011; 102:331-7. [PMID: 22115321 DOI: 10.1111/j.1423-0410.2011.01568.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVES Most patients with myelodysplastic syndrome (MDS) require blood product support to manage the severe anaemias, which frequently accompany MDS. Our objective was to show the feasibility of linking the Surveillance, Epidemiology and End Results (SEER) database with records from Puget Sound Blood Center (PSBC) to characterize blood product use over time in successive cohorts of patients with MDS. MATERIALS AND METHODS We identified patients with MDS in the SEER registry. The cohort was then linked to PSBC records to discern blood product use. RESULTS Included in the analysis were 783 patients with MDS entered in the SEER database from 2001 to 2007 for whom data were also available in the PSBC database. Among patients with MDS who received transfusions, 97% received packed red blood cells; 52% received platelets. The proportion of patients with MDS receiving blood products declined from 2001 to 2007. CONCLUSION These data show a recent decline in blood product use for patients with MDS. Future studies are needed to further evaluate the reasons for this finding, specifically exploring the impact of newer medications on blood product use in patients with MDS.
Collapse
Affiliation(s)
- S D Ramsey
- Research and Economic Assessment in Cancer and Healthcare (REACH) Group, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
| | | | | | | | | | | | | |
Collapse
|
5
|
Gonzalez-Angulo AM, Barlow WE, Gralow J, Meric-Bernstam F, Hayes DF, Moinpour C, Ramsey SD, Schott AF, Sparks DB, Albain KS, Hortobagyi GN. SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps104] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Shankaran V, Beck SJ, Blough DK, Koepl L, Yim YM, Yu E, Ramsey SD. Survival trends and patterns of chemotherapy use in elderly metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
|
8
|
Roth JA, Carlson JJ, Steuten L, Ramsey SD, Veenstra DL. The value of research for ERCC1 testing in stage I non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e16544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Ramsey SD, Barlow WE, Moinpour C, Gonzalez-Angulo AM, Hortobagyi GN, Veenstra DL, Garrison LP, Tunis SR, Baker LH. Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Shankaran V, Beck SJ, Blough DK, Yim Y, Yu E, Ramsey SD. Patterns of care and survival trends in elderly metastatic colorectal cancer patients: A SEER-Medicare analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
520 Background: Over the last decade, the treatment of metastatic colorectal cancer (mCRC) has changed dramatically as new drugs and hepatic resection have been incorporated into practice. The goal of this study is to examine treatment patterns and survival trends for older patients (pts) with mCRC. Methods: Pts ≥ age 65 with mCRC diagnosed (dx) 2001-2005 were identified from the SEER-Medicare database. Pts were excluded for lack of Medicare parts A and B in the year prior to dx, second malignancy, or non- adenocarcinoma histology. First-line (1L) chemotherapy (CTx) use was identified by claims within 3 months of dx. Metastatectomy was identified by various claims for liver resection. Comorbidity was assessed by Klabunde index. A Cox proportional hazards regression model was used to assess the effect of demographic and treatment factors on survival. Results: A total of 5,725 pts (median age 77) met inclusion criteria. 274 pts (5%) underwent hepatic resection and 2,647 (46%) received CTx. From 2001-2003, 43% of pts received 1L CTx (34% and 1% with regimens containing irinotecan (Iri) and oxaliplatin (Ox) and 49% with 5-FU/cap alone). From 2004-2005, 51% of pts received 1L CTx (25%, 14%, and 37% with regimens containing bevacizumab (Bv), Iri, and Ox and 40% with 5-FU/cap alone). In the multivariate analysis using the Cox proportional hazards model, survival was significantly improved in pts receiving CTx or hepatic resection and in pts dx 2004-2005 (Table). Conclusions: In an older mCRC population, hepatic resection, CTx use, and mCRC dx in 2004-2005 are associated with improved survival. Improved survival of pts dx in 2004-2005 coincides with the 2004 approval dates and uptake of Bv and Ox, and may be associated with the use of these therapies. Further analysis will examine the associations between specific Ctx regimens, Bv, and survival and will include pts dx through 2007. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- V. Shankaran
- Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Genentech, South San Francisco, CA
| | - S. J. Beck
- Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Genentech, South San Francisco, CA
| | - D. K. Blough
- Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Genentech, South San Francisco, CA
| | - Y. Yim
- Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Genentech, South San Francisco, CA
| | - E. Yu
- Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Genentech, South San Francisco, CA
| | - S. D. Ramsey
- Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Genentech, South San Francisco, CA
| |
Collapse
|
11
|
Goulart BL, Ramsey SD. Initial use of newer agents for advanced non-small cell lung cancer: Evidence from the National Cancer Institute Patterns of Care study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
|
13
|
Carlson J, Oestreicher N, Lubeck DP, Ramsey SD, Veenstra DL. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7664] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7664 Background: Multiple treatment strategies are now available for stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of 1st line treatment, but their relative economic and clinical value is not clear. Methods: We developed a health state transition model with 3 health states (progression free, disease progression, and death) to estimate the direct medical costs and quality-adjusted life-years (QALYs) of treating refractory NSCLC from the US healthcare system perspective. The treatments considered were erlotinib, docetaxel, and pemetrexed, and the time horizon was 2 years. Mean survival and progression free survival were assumed equal for all three treatments based on published pivotal clinical trials; side effect data were derived from the same studies. Utilities were obtained from a recent community-based study performed in the UK. Costs were obtained from published sources, and costs and effects were discounted at 3%. Sensitivity analyses were performed to evaluate uncertainty in the results. Results: Total costs in the base case were $31,000 for erlotinib, $33,700 for docetaxel, and $38,200 for pemetrexed. Drug acquisition and administration costs were $11,800, $12,200, and $18,700, respectively. Adverse event costs were $200, $2,500, and $500 on average per patient, and disease costs were equivalent at $19,000. QALYs were slightly greater for erlotinib versus docetaxel and pemetrexed (an increase of 0.02 and 0.01, respectively), due to differences in side effect profiles. The cost differences were robust to sensitivity analyses; when the utility for IV vs. oral therapy were assumed equal, erlotinib had 0.1 greater QALY than docetaxel and equivalent QALYs to pemetrexed. Conclusions: The results of our study suggest erlotinib in the treatment of refractory NSCLC in the United States is cost-saving compared with alternative treatments, with a slight improvement in patient quality of life. The results of ongoing comparative clinical trials will be useful for further evaluation of potential survival benefits. [Table: see text]
Collapse
Affiliation(s)
- J. Carlson
- University of Washington, Seattle, WA; Genentech, Inc., South San Francisco, CA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - N. Oestreicher
- University of Washington, Seattle, WA; Genentech, Inc., South San Francisco, CA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - D. P. Lubeck
- University of Washington, Seattle, WA; Genentech, Inc., South San Francisco, CA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - S. D. Ramsey
- University of Washington, Seattle, WA; Genentech, Inc., South San Francisco, CA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - D. L. Veenstra
- University of Washington, Seattle, WA; Genentech, Inc., South San Francisco, CA; Fred Hutchinson Cancer Research Center, Seattle, WA
| |
Collapse
|
14
|
Ramsey SD, Sullivan SD, Malin J, Blough DK, Clarke L, McCune JS. Colony stimulating factor use and outcomes for breast, lung, and colorectal cancer patients in Washington State. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6616] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6616 Background: Guidelines recommend colony stimulating factor (CSF) primary prophylaxis (PP) with chemotherapy if febrile neutropenia risk (FN) is =20%. Use of and outcomes for persons receiving CSF in clinical practice are relatively unknown. Methods: Using claims for Medicare and Medicaid enrollees linked to the Puget Sound SEER registry, breast (BCa), lung (LCa) and colorectal cancer (CRCa) patients diagnosed 2002–04 who received chemotherapy were categorized as: CSF at the start of chemotherapy (PP); other CSF; no CSF. Logistic regression was used to determine predictors of CSF PP and hospitalization for FN, controlling for cancer stage, age, sex, race, chemotherapy FN risk (from the National Comprehensive Cancer Network), radiation therapy, CSF use, health insurance, surgery =30 days of chemotherapy. Results: 364 BCa, 908 LCa, and 452 CRCa patients received chemotherapy. 43% of BCa, 30% of LCa, and 15% of CRCa patients received CSF. Only 9%, 6%, and 0.6% of patients initiated CSF as PP in the first cycle of chemotherapy. CSF use increased for all cancers, but most for BCa, (36% in 2002 to 70% in 2004); PP increased from 5% to 26%. Significant predictors (p<0.05) of PP were: BCa–local vs distant stage (OR 0.2), regional vs distant (OR 0.6), chemotherapy FN risk high vs low (OR 6.7); LCa–chemotherapy FN risk high vs low (OR 8.9), intermediate vs low (OR 6.3). FN incidence was 11%, 18% and 32% for BCa, CRCa, LCa, respectively. Significant predictors of FN were: BCa–nonwhite race (OR 2.7); LCa–surgery within 30 days (OR 1.7); CRCa–regional vs. distant (OR 0.4) and chemotherapy FN risk intermediate vs. low (OR 4.2). Conclusions: CSF use has increased significantly, but often in settings where efficacy is uncertain. Cancer type, stage and chemotherapy risk of FN influenced use of primary prophylaxis. Non-chemotherapy factors also appear to influence risk for FN. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. D. Ramsey
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Amgen Inc, Thousand Oaks, CA; Cornerstone Systems Northwest, Lynden, WA; Seattle Cancer Care Alliance, Seattle, WA
| | - S. D. Sullivan
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Amgen Inc, Thousand Oaks, CA; Cornerstone Systems Northwest, Lynden, WA; Seattle Cancer Care Alliance, Seattle, WA
| | - J. Malin
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Amgen Inc, Thousand Oaks, CA; Cornerstone Systems Northwest, Lynden, WA; Seattle Cancer Care Alliance, Seattle, WA
| | - D. K. Blough
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Amgen Inc, Thousand Oaks, CA; Cornerstone Systems Northwest, Lynden, WA; Seattle Cancer Care Alliance, Seattle, WA
| | - L. Clarke
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Amgen Inc, Thousand Oaks, CA; Cornerstone Systems Northwest, Lynden, WA; Seattle Cancer Care Alliance, Seattle, WA
| | - J. S. McCune
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; Amgen Inc, Thousand Oaks, CA; Cornerstone Systems Northwest, Lynden, WA; Seattle Cancer Care Alliance, Seattle, WA
| |
Collapse
|
15
|
Zeliadt SB, Etzioni R, Penson DF, Ramsey SD. Cost-effectiveness and lifetime implications of using finasteride to reduce prostate cancer incidence and mortality. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. B. Zeliadt
- University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Southern California/Norris Cancer Center, Los Angeles, CA
| | - R. Etzioni
- University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Southern California/Norris Cancer Center, Los Angeles, CA
| | - D. F. Penson
- University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Southern California/Norris Cancer Center, Los Angeles, CA
| | - S. D. Ramsey
- University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Southern California/Norris Cancer Center, Los Angeles, CA
| |
Collapse
|
16
|
Ramsey SD, Freedman AN, Berry K, Andersen MR, Urban N. Prevalence of pedigrees suggestive of hereditary nonpolyposis colorectal cancer among a community sample of women eligible for screening mammography. Public Health Genomics 2004; 2:173-8. [PMID: 14960838 DOI: 10.1159/000016208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE To determine from a large cohort of women eligible for screening mammography, the number who would meet criteria for genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC). METHODS Detailed personal and family cancer histories, obtained from 6,682 women aged 50-80 years randomly selected from communities in Washington State, were matched to the Amsterdam criteria, Bethesda guidelines, and Japanese criteria for HNPCC. RESULTS One (0.015%) respondent met the Amsterdam criteria, 2 (0.035%) met the Japanese criteria and 5 (0.075%) met the Bethesda guidelines. CONCLUSION Using the time of presentation for initial mammography as an opportunity to screen for HNPCC would detect very few families at high risk for this condition.
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle 98103, USA.
| | | | | | | | | |
Collapse
|
17
|
Abstract
In today's cost-conscious environment, understanding the economic implications associated with disease processes and their treatments is as important as understanding their clinical impact. Medical expenditures for treating chronic obstructive pulmonary disease (COPD) and the indirect costs of morbidity can represent a substantial economic and social burden. Very little economic information concerning COPD is available, however, particularly outside of a few very well-developed Western nations. This article will provide an approach for conducting high-quality studies aimed at estimating the economic burden of chronic obstructive pulmonary disease and for making economic evaluations of healthcare interventions aimed at preventing and treating this disease.
Collapse
Affiliation(s)
- S D Ramsey
- Fred Hutchinson Cancer Research Center, Dept of Pharmacy, University of Washington, Seattle, WA 98109, USA.
| | | |
Collapse
|
18
|
Abstract
OBJECTIVES The goal of this study was to determine whether outcomes of nonemergent coronary artery bypass grafting (CABG) differed between low- and high-volume hospitals in patients at different levels of surgical risk. BACKGROUND Regionalizing all CABG surgeries from low- to high-volume hospitals could improve surgical outcomes but reduce patient access and choice. "Targeted" regionalization could be a reasonable alternative, however, if subgroups of patients that would clearly benefit from care at high-volume hospitals could be identified. METHODS We assessed outcomes of CABG at 56 U.S. hospitals using 1997 administrative and clinical data from Solucient EXPLORE, a national outcomes benchmarking database. Predicted in-hospital mortality rates for subjects were calculated using a logistic regression model, and subjects were classified into five groups based on surgical risk: minimal (< 0.5%), low (0.5% to 2%), moderate (2% to 5%), high (5% to 20%), and severe (> or =20%). We assessed differences in in-hospital mortality, hospital costs and length of stay between low- and high-volume facilities (defined as > or =200 annual cases) in each of the five risk groups. RESULTS A total of 2,029 subjects who underwent CABG at 25 low-volume hospitals and 11,615 subjects who underwent CABG at 31 high-volume hospitals were identified. Significant differences in in-hospital mortality were seen between low- and high-volume facilities in subjects at moderate (5.3% vs. 2.2%; p = 0.007) and high risk (22.6% vs. 11.9%; p = 0.0026) but not in those at minimal, low or severe risk. Hospital costs and lengths of stay were similar across each of the five risk groups. Based on these results, targeted regionalization of subjects at moderate risk or higher to high-volume hospitals would have resulted in an estimated 370 transfers and avoided 16 deaths; in contrast, full regionalization would have led to 2,029 transfers and avoided 20 deaths. CONCLUSIONS Targeted regionalization might be a feasible strategy for balancing the clinical benefits of regionalization with patients' desires for choice and access.
Collapse
Affiliation(s)
- B K Nallamothu
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109-0366, USA
| | | | | | | | | | | |
Collapse
|
19
|
Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001; 135:577-88. [PMID: 11601929 DOI: 10.7326/0003-4819-135-8_part_1-200110160-00008] [Citation(s) in RCA: 97] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND The National Cancer Institute has published consensus guidelines for universal screening for hereditary nonpolyposis colorectal cancer (HNPCC) in patients with newly diagnosed colorectal cancer. OBJECTIVE To determine the cost-effectiveness of screening compared with standard care in eligible patients with colorectal cancer and their siblings and children. DESIGN Cost-effectiveness analysis. DATA SOURCES National colorectal cancer registry data, the Creighton International Hereditary Colorectal Cancer Registry, Medicare claims records, and published literature. TARGET POPULATION Patients with newly diagnosed colorectal cancer and their siblings and children. TIME HORIZON Lifetime (varies depending on age at screening). PERSPECTIVE Societal. INTERVENTIONS Initial office-based screening to determine eligibility (based on personal and family cancer history), followed by tumor testing for microsatellite instability. Those with microsatellite instability were offered genetic testing for HNPCC. Siblings and children of patients with cancer and the HNPCC mutation were offered genetic testing, and those who were found to carry the mutation received lifelong colorectal cancer screening. MEASUREMENTS Life-years gained. RESULTS OF BASE-CASE ANALYSIS When only the patients with cancer were considered, cost-effectiveness of screening was $42 210 per life-year gained. When patients with cancer and their siblings and children were considered together, cost-effectiveness increased to $7556 per life-year gained. RESULTS OF SENSITIVITY ANALYSIS The model was most sensitive to the estimated survival gain from screening siblings and children, to the prevalence of HNPCC mutations among patients with newly diagnosed cancer, and to the discount rate. In probabilistic analysis, the 90% CI for the cost-effectiveness of screening patients with cancer plus their relatives was $4874 to $21 576 per life-year gained. CONCLUSION Screening patients with newly diagnosed colorectal cancer for HNPCC is cost-effective, especially if the benefits to their immediate relatives are considered.
Collapse
Affiliation(s)
- S D Ramsey
- Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North (MP-900), Box 19024, Seattle, WA 98109, USA.
| | | | | | | | | | | |
Collapse
|
20
|
Yueh B, Souza PE, McDowell JA, Collins MP, Loovis CF, Hedrick SC, Ramsey SD, Deyo RA. Randomized trial of amplification strategies. Arch Otolaryngol Head Neck Surg 2001; 127:1197-204. [PMID: 11587599 DOI: 10.1001/archotol.127.10.1197] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND Little is known about quality of life after the use of specific types of hearing aids, so it is difficult to determine whether technologies such as programmable circuits and directional microphones are worth the added expense. OBJECTIVE To compare the effectiveness of an assistive listening device, a nonprogrammable nondirectional microphone hearing aid, with that of a programmable directional microphone hearing aid against the absence of amplification. DESIGN Randomized controlled trial. SETTING Audiology clinic at the VA Puget Sound Health Care System, Seattle, Wash. PATIENTS Sixty veterans with bilateral moderate to severe sensorineural hearing loss completed the trial. Half the veterans (n = 30) had hearing loss that the Veterans Affairs clinic determined was rated as "service connected," which meant that they were eligible for Veterans Affairs-issued hearing aids. INTERVENTION Veterans with non-service-connected hearing loss, who were ineligible for Veterans Affairs-issued hearing aids, were randomly assigned to no amplification (control arm) or to receive an assistive listening device. Veterans with service-connected loss were randomly assigned to receive either the nonprogrammable hearing aid that is routinely issued ("conventional") or a programmable aid with a directional microphone ("programmable"). MAIN OUTCOME MEASURES Hearing-related quality of life, self-rated communication ability, adherence to use, and willingness to pay for the amplification devices (measured 3 months after fitting). RESULTS Clear distinctions were observed between all 4 arms. The mean improvement in hearing-related quality of life (Hearing Handicap Inventory for the Elderly) scores was small for control patients (2.2 points) and patients who received an assistive listening device (4.4 points), excellent for patients who received a conventional device (17.4 points), and substantial for patients who received a programmable device (31.1 points) (P<.001 by the analysis of variance test). Qualitative analyses of free-text diary entries, self-reported communication ability (Abbreviated Profile of Hearing Aid Benefit) scores, adherence to hearing aid use, and willingness to pay for replacement devices showed similar trends. CONCLUSIONS A programmable hearing aid with a directional microphone had the highest level of effectiveness in the veteran population. A nonprogrammable hearing aid with an omnidirectional microphone was also effective compared with an assistive listening device or no amplification.
Collapse
Affiliation(s)
- B Yueh
- Surgery Service (112OTO), VA Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Ramsey SD, Cheadle AD, Neighbor WE, Gore E, Temple P, Staiger T, Goldberg HI. Relative impact of patient and clinic factors on adherence to primary care preventive service guidelines: an exploratory study. Med Care 2001; 39:979-89. [PMID: 11502955 DOI: 10.1097/00005650-200109000-00008] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Preventive care service use is commonly compared across health plans, clinics, or individual providers, yet little is known about the influence of the clinic versus patient factors on utilization of these services. OBJECTIVES To measure the relative influence of the facility (clinic) versus patient factors (demographic, behavioral and functional characteristics) on patients' utilization of mammography, Pap smears, cholesterol screening, and retinal exams for those with diabetes. RESEARCH DESIGN Retrospective analysis, using administrative and patient survey data. SUBJECTS Enrollees in 2 University-based clinics and a county hospital-based clinic serving a predominantly low-income population with limited access to health care. Eligibility for cervical cancer screening, screening mammography, cholesterol screening, or annual retinal exam (diabetes) was defined by age, sex, and diagnosis. MEASURES Multivariate models, one using readily available administrative data, and another using detailed health status and behavior data gathered from a clinics-wide survey. RESULTS Unadjusted screening rates for three of four procedures were significantly and substantially lower at the county hospital based clinic than the two University-based clinics. After adjusting for patient characteristics, utilization of three screening services at the county hospital remained significantly below the University-based clinics (Odds Ratios [95% CI]: mammogram 0.15 [0.06-0.35]; Pap smear 0.32 [0.21-0.50]; cholesterol 0.19 [0.09-0.38]; diabetes retinal exam10.68 [0.93-3.01]). The models with detailed survey data performed only marginally better than the models using only administrative data. CONCLUSIONS Patient characteristics were much less important than the clinic for predicting whether patients received primary care preventive services. Our results suggest that case mix adjustment is unlikely to explain away discrepancies in performance between clinics or provider groups.
Collapse
Affiliation(s)
- S D Ramsey
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
| | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
BACKGROUND While the efficacy and safety of coronary artery bypass grafting (CABG) has been established in several clinical trials, little is known about its outcomes in Native Americans. MEASUREMENTS AND MAIN RESULTS We assessed clinical outcomes associated with CABG in 155 Native Americans using a national database of 18,061 patients from 25 nongovernmental, not-for-profit U.S. health care facilities. Patients were classified into five groups: 1) Native American, 2) white, 3) African American, 4) Hispanic, and 5) Asian. We evaluated for ethnic differences in in-hospital mortality and length of stay, and after adjusting for age, gender, surgical priority, case-mix severity, insurance status, and facility characteristics (volume, location, and teaching status). Overall, we found the adjusted risk for in-hospital death to be higher in Native Americans when compared to whites (odds ratio [OR], 3.8; 95% confidence interval [CI], 1.5 to 9.8), African Americans (OR, 3.4; 95% CI, 1.1 to 9.9), Hispanics (OR, 7.1; 95% CI, 2.5 to 20.3), and Asians (OR, 2.8; 95% CI, 1.1 to 7.0). No significant differences were found in length of stay after adjustment across ethnic groups. CONCLUSIONS The risk of in-hospital death following CABG may be higher in Native Americans than in other ethnic groups. Given the small number of Native Americans in the database (n = 155), however, further research will be needed to confirm these findings.
Collapse
Affiliation(s)
- B K Nallamothu
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor 48109-0022, USA.
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
In response to rising demands for timely economic data on new medical technologies, cost-effectiveness studies are increasingly being conducted alongside clinical trials. Because of the historical differences in perspective and methods between cost-effectiveness studies and clinical trials, the design phase of these hybrid trials requires special consideration. Cost-effectiveness studies require more comprehensive evaluations of outcomes than the endpoints typically measured in clinical trials. Often, these comprehensive outcome measures (such as quality of life) prove useful for interpreting the other endpoints measured in the trial, as well as for estimating the cost-effectiveness of the intervention. In this manuscript, we discuss several aspects related to the design of joint clinical/economic trials, including study perspective, hypothesis testing, sample size estimation, and methods for collecting cost and outcome data. We also discuss issues that may limit the external validity of the cost-effectiveness results of these trials. Many potential threats to external validity can be successfully addressed if they are identified and accounted for in the design phase of the study.
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
| | | | | |
Collapse
|
24
|
Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-8. [PMID: 11432888 DOI: 10.1200/jco.2001.19.13.3210] [Citation(s) in RCA: 925] [Impact Index Per Article: 40.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This randomized trial was designed to determine whether paclitaxel plus carboplatin (PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for patients with advanced non--small-cell lung cancer. Secondary objectives were to compare toxicity, tolerability, quality of life (QOL), and resource utilization. PATIENTS AND METHODS Two hundred two patients received VC (vinorelbine 25 mg/m(2)/wk and cisplatin 100 mg/m(2)/d, day 1 every 28 days) and 206 patients received PC (paclitaxel 225 mg/m(2) over 3 hours with carboplatin area under the curve of 6, day 1 every 21 days). Patients completed QOL questionnaires at baseline, 13 weeks, and 25 weeks. Resource utilization forms were completed at five time points through 24 months. RESULTS Patient characteristics were similar between the groups. The objective response rate was 28% in the VC arm and 25% in the PC arm. Median survival was 8 months in both arms, with 1-year survival rates of 36% and 38%, respectively. Grade 3 and 4 leukopenia (P =.002) and neutropenia (P =.008) occurred more frequently on the VC arm. Grade 3 nausea and vomiting were higher on the VC arm (P =.001, P =.007), and grade 3 peripheral neuropathy was higher on the PC arm (P <.001). More patients on the VC arm discontinued therapy because of toxicity (P =.001). No difference in QOL was observed. Overall costs on the PC arm were higher than on the VC arm because of drug costs. CONCLUSION PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer. PC is less toxic and better tolerated but more expensive than VC. New treatment strategies should be pursued.
Collapse
Affiliation(s)
- K Kelly
- University of Colorado, Denver, CO, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
Dyslipidemia is very common in diabetics and substantially increases the risk of fatal and non-fatal cardiovascular disease. Pharmacological therapy with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ('statins') is effective for dyslipidemia, but the cost and efficacy of individual therapies vary. Therefore, the interest in cost-effective pharmacologic interventions for the prevention of cardiovascular disease events in diabetics has increased. In this article, the literature pertaining to the epidemiology, cost and efficacy of statins in preventing cardiovascular disease in patients with type 2 diabetes mellitus, in both the primary and secondary prevention settings, is reviewed. Cost-effectiveness studies of statins in the diabetic population are detailed, along with recommendations for further research.
Collapse
Affiliation(s)
- N Chaiyakunapruk
- Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
| | | | | |
Collapse
|
26
|
Abstract
OBJECTIVE To examine the rates of use and expenditures on alternative therapies by adults with osteoarthritis (OA). METHODS Adults with OA recruited from the community to participate in a randomized clinical trial recorded alternative and traditional health care use on postcard diaries. General and arthritis-specific quality of life was assessed by questionnaires. RESULTS More than 47% of participants reported using at least one type of alternative care during the 20-week intervention period. Among alternative care consumers, the most commonly used treatments were massage therapy (57%), chiropractic services (20.7%), and nonprescribed alternative medications (17.2%). Four percent of subjects reported using only alternative care during the study period. Expenditures for alternative therapy averaged $1,127 per year, compared with $1,148 for traditional therapies. CONCLUSION Use of and expenditures for alternative care were high among this cohort of older adults with OA. Clinicians may want to inquire about use of these therapies before recommending treatments for this condition.
Collapse
Affiliation(s)
- S D Ramsey
- Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
| | | | | | | | | |
Collapse
|
27
|
Abstract
OBJECTIVES To estimate cost and outcomes of the Arthritis Foundation aquatic exercise classes from the societal perspective. DESIGN Randomized trial of 20-week aquatic classes. Cost per quality-adjusted life year (QALY) gained was estimated using trial data. Sample size was based on 80% power to reject the null hypothesis that the cost/QALY gained would not exceed $50,000. SUBJECTS AND METHODS Recruited 249 adults from Washington State aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in aquatic classes. The Quality of Well-Being Scale (QWB) and Current Health Desirability Rating (CHDR) were used for economic evaluation, supplemented by the arthritis-specific Health Assessment Questionnaire (HAQ), Center for Epidemiologic Studies-Depression Scale (CES-D), and Perceived Quality of Life Scale (PQOL) collected at baseline and postclass. Outcome results applied to life expectancy tables were used to estimate QALYs. Use of health care facilities was assessed from diaries/questionnaires and Medicare reimbursement rates used to estimate costs. Nonparametric bootstrap sampling of costs/QALY ratios established the 95% CI around the estimates. RESULTS Aquatic exercisers reported equal (QWB) or better (CHDR, HAQ, PQOL) health-related quality of life compared with controls. Outcomes improved with regular class attendance. Costs/QALY gained discounted at 3% were $205,186 using the QWB and $32,643 using the CHRD. CONCLUSION Aquatic exercise exceeded $50,000 per QALY gained using the community-weighted outcome but fell below this arbitrary budget constraint when using the participant-weighted measure. Confidence intervals around these ratios suggested wide variability of cost effectiveness of aquatic exercise.
Collapse
Affiliation(s)
- D L Patrick
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
| | | | | | | | | | | |
Collapse
|
28
|
Etzioni R, Ramsey SD, Berry K, Brown M. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Econ 2001; 10:245-256. [PMID: 11288190 DOI: 10.1002/hec.580] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
A source of controversy in the economic literature concerns whether to include or exclude future medical care costs when computing attributable costs for lifesaving interventions. Although it is hypothesized that including future medical care costs will offset the cost savings achieved through prevention, the magnitude of the effect is not known. The objectives of the present study are to develop a methodology for estimating the excess costs of care among colorectal cancer patients, including and excluding future costs of care, and comparing these results with previous studies that do not include costs in added years of life. Subjects in the study included those identified with colorectal cancer drawn from the Surveillance, Epidemiology and End Results (SEER)-Medicare database and an age- and gender-matched control group drawn from the general Medicare population. Using the Kaplan-Meier Sample Average estimator, we directly estimate expected 11-year costs, and then, with the addition of some simple extrapolating assumptions, determine expected 25-year costs. The latter time horizon captures lifetime costs for over 90% of the cohort. Males results for discounted, stage-specific 11- versus 25-year excess costs: in situ, 22411 dollars versus 23494 dollars; Stage 1, 29365 dollars versus 32510 dollars; Stage 2, 28114 dollars versus 25263 dollars; Stage 3, 27397 dollars versus 19647 dollars; Stage 4, 3006 dollars versus 7837 dollars. Trends were similar for females. It can be concluded that adding costs of care in future years for those whose colorectal cancer is prevented owing to screening greatly alters the estimate of lifetime excess costs for colorectal cancer patients, and can produce negative results for advanced stage disease. The results emphasize the need to adopt a standard approach for dealing with future costs when evaluating lifesaving interventions for cost-effectiveness analyses.
Collapse
Affiliation(s)
- R Etzioni
- Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | | | | | | |
Collapse
|
29
|
Ramsey SD, Sullivan SD, Kaplan RM, Wood DE, Chiang YP, Wagner JL. Economic analysis of lung volume reduction surgery as part of the National Emphysema Treatment Trial. NETT Research Group. Ann Thorac Surg 2001; 71:995-1002. [PMID: 11269488 DOI: 10.1016/s0003-4975(00)02283-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND In today's cost-conscious health care environment, obtaining timely and accurate economic information regarding new medical technologies has become extremely important. The National Emphysema Treatment Trial, a multicenter, randomized controlled trial of lung volume reduction surgery (LVRS) plus medical therapy, versus medical therapy for patients with severe emphysema, includes a parallel cost-effectiveness analysis. METHODS The analysis is designed to determine the cost-effectiveness of LVRS versus medical therapy for those who are eligible for the procedure. After describing theoretical foundations of cost-effectiveness analysis as they apply to this study, we describe the economic and quality of life data that are being collected alongside the clinical trial, methods of analysis, and approach to presenting the results. RESULTS The cost-effectiveness of LVRS relative to medical therapy will be presented as costs per quality-adjusted life years gained. CONCLUSIONS This analysis will provide timely economic data that can be considered alongside the clinical results of the National Emphysema Treatment Trial. As one of the largest clinical trials to include a parallel, prospective cost-effectiveness analyses, this study will also provide valuable practical information about conducting an economic analysis alongside a multicenter clinical trial.
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle, USA.
| | | | | | | | | | | |
Collapse
|
30
|
Abstract
CONTEXT Because of the additional costs associated with improving diabetes management, there is interest in whether improved glycemic control leads to reductions in health care costs, and, if so, when such cost savings occur. OBJECTIVE To determine whether sustained improvements in hemoglobin A(1c) (HbA(1c)) levels among diabetic patients are followed by reductions in health care utilization and costs. DESIGN AND SETTING Historical cohort study conducted in 1992-1997 in a staff-model health maintenance organization (HMO) in western Washington State. PARTICIPANTS All diabetic patients aged 18 years or older who were continuously enrolled between January 1992 and March 1996 and had HbA(1c) measured at least once per year in 1992-1994 (n = 4744). Patients whose HbA(1c) decreased 1% or more between 1992 and 1993 and sustained the decline through 1994 were considered to be improved (n = 732). All others were classified as unimproved (n = 4012). MAIN OUTCOME MEASURES Total health care costs, percentage hospitalized, and number of primary care and specialty visits among the improved vs unimproved cohorts in 1992-1997. RESULTS Diabetic patients whose HbA(1c) measurements improved were similar demographically to those whose levels did not improve but had higher baseline HbA(1c) measurements (10.0% vs 7.7%; P<.001). Mean total health care costs were $685 to $950 less each year in the improved cohort for 1994 (P =.09), 1995 (P =.003), 1996 (P =.002), and 1997 (P =.01). Cost savings in the improved cohort were statistically significant only among those with the highest baseline HbA(1c) levels (>/=10%) for these years but appeared to be unaffected by presence of complications at baseline. Beginning in the year following improvement (1994), utilization was consistently lower in the improved cohort, reaching statistical significance for primary care visits in 1994 (P =.001), 1995 (P<.001), 1996 (P =.005), and 1997 (P =.004) and for specialty visits in 1997 (P =.02). Differences in hospitalization rates were not statistically significant in any year. CONCLUSION Our data suggest that a sustained reduction in HbA(1c) level among adult diabetic patients is associated with significant cost savings within 1 to 2 years of improvement.
Collapse
Affiliation(s)
- E H Wagner
- MacColl Institute for Healthcare Innovation, Center for Health Studies, Group Health Cooperative, 1730 Minor Ave, Suite 1290, Seattle, WA 98101, USA.
| | | | | | | | | | | |
Collapse
|
31
|
Lee TA, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJ, Malinverni R, Pleil AM, Williamson T. Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics 2001; 19:535-550. [PMID: 11465299 DOI: 10.2165/00019053-200119050-00008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
OBJECTIVE To determine the cost of using systemic therapy to treat newly diagnosed cytomegalovirus (CMV) retinitis in persons with AIDS. DESIGN Incidence-based simulation model of CMV treatment from a government payer perspective. SETTING Swiss healthcare system. PATIENTS AND PARTICIPANTS Patients with AIDS and newly diagnosed CMV retinitis. INTERVENTIONS Patients were assigned to 1 of 4 treatment regimens for induction and maintenance therapy: (i) intravenous (IV) cidofovir induction and maintenance (cidofovir IV/IV); (ii) IV foscarnet induction and maintenance (foscarnet IV/IV); (iii) IV ganciclovir induction and maintenance (ganciclovir IV/IV); and (iv) IV ganciclovir induction and oral (PO) ganciclovir maintenance (ganciclovir IV/PO). Following a second relapse, patients were assigned to one of the other regimens. MAIN OUTCOME MEASURES Time to first and subsequent progression, duration of maintenance treatment and direct medical expenditures [1998 Swiss francs (SwF)] . RESULTS The median time to first progression was longest for cidofovir IV/IV, followed by foscarnet IV/IV, ganciclovir IV/IV and ganciclovir IV/PO. Mean survival was 13 months and mean costs for this period in the base case were lowest in those initially treated with cidofovir (SwF146,742), followed by initial treatment with foscarnet IV/IV (SwF194,809), ganciclovir IV/PO (SwF195,190) and ganciclovir IV/IV (SwF243,964). Costs were most sensitive to changes in efficacy estimates. CONCLUSIONS Of the regimens studied, initiation of treatment with systemic cidofovir appears least costly over a 13-month period.
Collapse
Affiliation(s)
- T A Lee
- Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle 98195, USA.
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Modeling will continue to be used to address important issues in clinical practice and health policy issues that have not been adequately studied with high-quality clinical trials. The apparent ad hoc nature of models belies the methodologic rigor that is applied to create the best models in cancer prevention and care. Models have progressed from simple decision trees to extremely complex microsimulation analyses, yet all are built using a logical process based on objective evaluation of the path between intervention and outcome. The best modelers take great care to justify both the structure and content of the model and then test their assumptions using a comprehensive process of sensitivity analysis and model validation. Like clinical trials, models sometimes produce results that are later found to be invalid as other data become available. When weighing the value of models in health care decision making, it is reasonable to consider the alternatives. In the absence of data, clinical policy decisions are often based on the recommendations of expert opinion panels or on poorly defined notions of the standard of care or medical necessity. Because such decision making rarely entails the rigorous process of data collection, synthesis, and testing that is the core of well-conducted modeling, it is usually not possible for external audiences to examine the assumptions and data that were used to derive the decisions. One of the modeler's most challenging tasks is to make the structure and content of the model transparent to the intended audience. The purpose of this article is to clarify the process of modeling, so that readers of models are more knowledgeable about their uses, strengths, and limitations.
Collapse
Affiliation(s)
- S D Ramsey
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
| | | | | | | |
Collapse
|
33
|
Abstract
BACKGROUND Colon carcinoma is a common malignancy that accounts for a substantial share of all cancer-related morbidity and mortality. However, little is known with regard to general and disease specific quality of life in survivors of colorectal carcinoma, particularly from community-based samples of cases across stage and survival times from diagnosis. METHODS Subjects with colorectal carcinoma were recruited from the National Cancer Institute's Surveillance, Epidemiology, and End Results cancer registry. Subjects completed two self-administered surveys: the Functional Assessment of Cancer Therapy Scales for Colorectal Cancer (FACT-C) and the Health Utilities Index (HUI) Mark III. RESULTS One hundred seventy-three respondents (average age: 70.4 years, 71.4% female) completed the survey. In the first 3 years after diagnosis, quality of life was lower and varied substantially among respondents. After 3 years, respondents in all TNM stages of disease except Stage IV reported a relatively uniform and high quality of life. Pain, functional well-being, and social well-being were affected most substantially across all stages and times from diagnosis. Low income status was associated with worse outcomes for pain, ambulation, and social and emotional well-being. Only emotional well-being scores improved significantly over time in both surveys. CONCLUSIONS Those individuals who achieve a long term remission from colorectal carcinoma may experience a relatively high quality of life, although deficits remain for several areas, particularly in those of low socioeconomic status. Sampling design may have excluded the most severely ill patients.
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle, Washington, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Ramsey SD, Saint S, Sullivan SD, Dey L, Kelley K, Bowdle A. Clinical and economic effects of pulmonary artery catheterization in nonemergent coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2000; 14:113-8. [PMID: 10794325 DOI: 10.1016/s1053-0770(00)90001-6] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To examine the association between use of pulmonary artery catheterization with hospital outcomes and costs in nonemergent coronary artery bypass graft (CABG) surgery. DESIGN Retrospective cohort study. SETTING Fifty-six community-based hospitals in 26 states. PARTICIPANTS A total of 13,907 patients undergoing nonemergent CABG surgery between January 1, 1997, and December 31, 1997. MEASUREMENTS AND MAIN RESULTS Discharge abstracts for each patient were examined. Stratified and multivariate analyses were used to assess the impact of pulmonary artery catheters (PACs) on in-hospital mortality, length of stay in the intensive care unit, total length of stay, and hospital costs. Outcomes were adjusted for patient demographic factors, hospital characteristics, and hospital volume of PAC use in the year of analysis. Fifty-eight percent of the patients received a PAC. After adjustment, the relative risk of in-hospital mortality was 2.10 for the PAC group compared with the patients who did not receive a PAC (95% confidence interval [CI], 1.40 to 3.14; p < 0.001). The mortality risk was significantly higher in hospitals with the lowest third of PAC use (odds ratio, 3.35; 95% CI, 1.74 to 6.47; p < 0.001) and not significantly increased in the highest two thirds of users (odds ratio, 1.62; 95% CI, 0.99 to 2.66; p = 0.09). Days spent in critical care were similar; however, total length of hospital stay was 0.26 days longer in the PAC group (p < 0.001). Hospital costs were $1,402 higher in the PAC group. CONCLUSION In the setting of nonemergent CABG surgery, pulmonary artery catheterization was associated with an increased risk of in-hospital mortality, greater length of stay, and higher total costs, particularly in hospitals with low volume of PAC use.
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle 98103, USA
| | | | | | | | | | | |
Collapse
|
35
|
Goldberg HI, Neighbor WE, Cheadle AD, Ramsey SD, Diehr P, Gore E. A controlled time-series trial of clinical reminders: using computerized firm systems to make quality improvement research a routine part of mainstream practice. Health Serv Res 2000; 34:1519-34. [PMID: 10737451 PMCID: PMC1975658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
OBJECTIVE To explore the feasibility of conducting unobtrusive interventional research in community practice settings by integrating firm-system techniques with time-series analysis of relational-repository data. STUDY SETTING A satellite teaching clinic divided into two similar, but geographically separated, primary care group practices called firms. One firm was selected by chance to receive the study intervention. Forty-two providers and 2,655 patients participated. STUDY DESIGN A nonrandomized controlled trial of computer-generated preventive reminders. Net effects were determined by quantitatively combining population-level data from parallel experimental and control interrupted time series extending over two-month baseline and intervention periods. DATA COLLECTION Mean rates at which mammography, colorectal cancer screening, and cholesterol testing were performed on patients due to receive each maneuver at clinic visits were the trial's outcome measures. PRINCIPAL FINDINGS Mammography performance increased on the experimental firm by 154 percent (0.24 versus 0.61, p = .03). No effect on fecal occult blood testing was observed. Cholesterol ordering decreased on both the experimental (0.18 versus 0.1 1, p = .02) and control firms (0.13 versus 0.07, p = .03) coincident with national guidelines retreating from recommending screening for young adults. A traditional uncontrolled interrupted time-series design would have incorrectly attributed the experimental-firm decrease to the introduction of reminders. The combined analysis properly indicated that no net prompting effect had occurred, as the difference between firms in cholesterol testing remained stochastically stable over time (0.05 versus 0.04, p = .75). A logistic-regression analysis applied to individual-level data produced equivalent findings. The trial incurred no supplementary data collection costs. CONCLUSIONS The apparent validity and practicability of our reminder implementation study should encourage others to develop computerized firm systems capable of conducting controlled time-series trials.
Collapse
Affiliation(s)
- H I Goldberg
- University of Washington, Department of Medicine, USA
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Effective outpatient management of COPD requires prescription of and adherence to appropriate therapies. Although practice guidelines for outpatient management of COPD are widely available, evidence suggests that these guidelines are not being implemented widely in clinical practice. Furthermore, several studies have shown that patient compliance with recommended therapy is poor. This paper discusses several reasons why implementation of practice guidelines and adherence with prescribed therapies may be poor. Potential clinical and economic consequences of suboptimal management are reviewed. Although the evidence suggests that improved compliance with guideline-recommended practice will improve symptoms and disease-specific quality of life, further work needs to be done to establish the cost-effectiveness of chronic therapies for COPD relative to other chronic conditions. Without such data, managed care organizations will be reluctant to allocate scarce resources toward expensive guideline implementation programs for individuals with this condition.
Collapse
Affiliation(s)
- S D Ramsey
- Departments of Medicine and Health Services, University of Washington, Seattle 98103, USA.
| |
Collapse
|
37
|
Abstract
COPD is one of the leading causes of morbidity and mortality worldwide and imparts a substantial economic burden on individuals and society. Despite the intense interest in COPD among clinicians and researchers, there is a paucity of data on health-care utilization, costs, and social burden in this population. The total economic costs of COPD morbidity and mortality in the United States were estimated at $23.9 billion in 1993. Direct treatments for COPD-related illness accounted for $14.7 billion, and the remaining $9.2 billion were indirect morbidity and premature mortality estimated as lost future earnings. Similar data from another US study suggest that 10% of persons with COPD account for > 70% of all medical care costs. International studies of trends in COPD-related hospitalization indicate that although the average length of stay has decreased since 1972, admissions per 1,000 persons per year for COPD have increased in all age groups > 45 years of age. These trends reflect population aging, smoking patterns, institutional factors, and treatment practices.
Collapse
Affiliation(s)
- S D Sullivan
- Departments of Pharmacy and Health Services, University of Washington, Seattle, WA 98195, USA.
| | | | | |
Collapse
|
38
|
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle, USA.
| |
Collapse
|
39
|
Ramsey SD, Sullivan SD. Weighing the economic evidence: guidelines for critical assessment of cost-effectiveness analyses. J Am Board Fam Pract 1999; 12:477-85. [PMID: 10612366 DOI: 10.3122/jabfm.12.6.477] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle 98195, USA
| | | |
Collapse
|
40
|
Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics 1999; 16:285-295. [PMID: 10558040 DOI: 10.2165/00019053-199916030-00005] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
OBJECTIVE To develop incidence-based estimates of the cost of several diabetes-related complications. DESIGN AND SETTING This was a retrospective cohort study in a large health maintenance organisation. A total of 8905 patients with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus and 36,520 age- and gender-matched controls without diabetes were observed from 1992 to 1995. Incidence rates of 6 major diabetes-related complications were computed for both populations. Annual health expenditures in the first and second year following diagnosis were computed for each complication. For comparison, annual costs were derived for individuals without diabetes or the complication of interest. MAIN OUTCOME MEASURES AND RESULTS Over 3 years of observation, incidence rates for the groups with and without diabetes were as follows: myocardial infarction 9.0 versus 3.2%; stroke 8.7 versus 3.8%; hypertension 26.2 versus 16.9%; end-stage renal disease 5.9 versus 1.4%; foot ulcer 7.9 versus 1.1%; and eye disease 44.3 versus 2.8%. Expressed as a multiple of the average annual cost of care for those without diabetes [$US3400/year (1995 dollars) for those over 65 years of age] and the related complication of interest, excess expenditures for those with diabetes were as follows for the first year following diagnosis: no complications 1.59; myocardial infarction 4.1; stroke 3.5; hypertension 2.56; end-stage renal disease 4.32; foot ulcer 4.0; and eye disease 2.46. For younger cohorts (less prevalent in the sample), incremental costs for each complication were generally greater than in the older group. CONCLUSIONS The high incidences and costs may support the value of aggressive early intervention for patients with diabetes. These data will be useful for pharmacoeconomic modelling of the cost effectiveness of new and existing therapies for this condition.
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle, USA.
| | | | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- S D Ramsey
- Department of Medicine and Health Services, University of Washington, Seattle 98103, USA
| |
Collapse
|
42
|
Pauly MV, Ramsey SD. Would you like suspenders to go with that belt? An analysis of optimal combinations of cost sharing and managed care. J Health Econ 1999; 18:443-458. [PMID: 10539616 DOI: 10.1016/s0167-6296(98)00055-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
When and why would it be efficient for a managed care insurance plan using managerial limits to add patient cost sharing? This paper uses a diagrammatic model to indicate that the use of patient point-of-service cost sharing can cause the managerial limits or guidelines to be less restrictive in limiting high value care for cases of severe illness. The model shows that cost-sharing is more likely to improve efficiency the greater the variation in illness severity and the smaller the degree of moral hazard. The model is extended to the case in which provider cost sharing is also used.
Collapse
Affiliation(s)
- M V Pauly
- Wharton School, University of Pennsylvania, Philadelphia 19104-6218, USA.
| | | |
Collapse
|
43
|
Abstract
Prostate cancer is a highly prevalent malignancy in older men. Because the disease and its treatments have the potential to cause substantial morbidity in affected individuals, prostate cancer has been the subject of great interest for quality-of-life (QOL) researchers. In this article, we review published QOL studies that have focused on individuals with prostate cancer. Generic survey instruments have generally been found to be insensitive to changes in health-related quality of life (HR-QOL) related to prostate cancer and its treatments. Domain-specific survey instruments (such as those focusing on sexual function) have been more sensitive, but fail to capture all relevant impacts. At least 9 disease-specific instruments have been developed to measure the HR-QOL impact of prostate cancer. These instruments generally focus on specific symptoms related to the disease and its treatment--urinary function, bowel function, sexual function, physical function, psychological function and pain--however, the domains covered are not consistent from instrument to instrument, and the domains of emphasis within each instrument are rarely the same. In addition, no single instrument has been applied to all major therapies for prostate cancer across men at different ages and stages of disease. Finally, HR-QOL evaluations in some patient groups, such as those with advanced disease, have received relatively little attention to date. As a result of the proliferation of prostate cancer-specific survey instruments and inconsistencies in their design and application, decision-makers face great difficulties evaluating HR-QOL across disease stages and comparing the HR-QOL impacts of alternative therapies, including conservative management ('watchful waiting'). In order for these tools to be useful for patient management and policy-making, coordination of instrument development efforts with the goal of consolidating the number of measures used is urgently needed.
Collapse
Affiliation(s)
- S D Sommers
- Department of Pharmacy, University of Washington, Seattle, USA
| | | |
Collapse
|
44
|
Abstract
PURPOSE To investigate the cost-effectiveness of computed tomography (CT) relative to radiography for cervical spine screening in trauma patients. MATERIALS AND METHODS A decision analysis model was constructed to compare the incremental cost-effectiveness of radiography and CT as primary cervical spine screening modalities in trauma patients. Analyses were performed from a societal perspective, and probability and cost estimates from the literature and institutional experience were used. In separate cost-effectiveness analyses, hypothetical cohorts of trauma patients from three defined clinical scenarios were considered: high, moderate, and low risk for cervical spine fracture. Outcome measures included cases of paralysis prevented, total cost of screening strategies, and incremental cost-effectiveness ratios. RESULTS In high-risk patients, screening with CT is a dominant strategy that prevents cases of paralysis and saves money for society. In moderate-risk patients, screening with CT is cost-effective with reference-case assumptions and within the range of most sensitivity analyses. In the low-risk group, CT screening helps prevent cases of paralysis, but the incremental cost-effectiveness ratio is high (> $80,000 per quality-adjusted life year). CONCLUSION CT is the preferred cervical spine screening modality in trauma patients at high and moderate risk for cervical spine fracture.
Collapse
Affiliation(s)
- C C Blackmore
- Department of Radiology, University of North Carolina-Chapel Hill School of Medicine 27599-7510, USA
| | | | | | | |
Collapse
|
45
|
Abstract
Measurement of treatment costs is important in the evaluation of medical interventions. Accurate cost estimation is problematic, when cost records are incomplete. Methods from the survival analysis literature have been proposed for estimating costs using available data. In this article, we clarify assumptions necessary for validity of these techniques. We demonstrate how assumptions needed for valid survival analysis may be violated when these methods are applied to cost estimation. Our observations are confirmed through simulations and empirical data analysis. We conclude that survival analysis approaches are not generally appropriate for the analysis of medical costs and review several valid alternatives.
Collapse
Affiliation(s)
- R D Etzioni
- Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
| | | | | | | | | | | |
Collapse
|
46
|
Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C. The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 1999; 52:199-207. [PMID: 10210237 DOI: 10.1016/s0895-4356(98)00161-9] [Citation(s) in RCA: 109] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We evaluated the accuracy of administrative data for identifying complications and comorbidities of diabetes using International Classification of Diseases, 9th edition, Clinical Modification and Current Procedural Terminology codes. The records of 471 randomly selected diabetic patients were reviewed for complications from January 1, 1993 to December 31, 1995; chart data served to validate automated data. The complications with the highest sensitivity determined by a diagnosis in the medical records identified within +/-60 days of the database date were myocardial infarction (95.2%); amputation (94.4%); ischemic heart disease (90.3%); stroke (91.2%); osteomyelitis (79.2%); and retinal detachment, vitreous hemorrhage, and vitrectomy (73.5%). With the exception of amputation (82.9%), positive predictive value was low when based on a diagnosis identified within +/-60 days of the database date but increased with relaxation of the time constraints to include confirmation of the condition at any time during 1993-1995: ulcers (88.5%); amputation (85.4%); and retinal detachment, vitreous hemorrhage and vitrectomy (79.8%). Automated data are useful for ascertaining potential cases of some diabetic complications but require confirmatory evidence when they are to be used for research purposes.
Collapse
Affiliation(s)
- K M Newton
- Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, Washington 98101, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract 1999; 12:105-14. [PMID: 10220232 DOI: 10.3122/jabfm.12.2.105] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND We wanted to determine the clinical cost of managing hypertension when following the Joint National Committee on Hypertension (JNC) guidelines, including drug therapy, the cost of monitoring for and treating side effects, compliance, and the cost of switching after therapeutic failures. METHODS The base-case analysis considers antihypertensive agents from four therapeutic classes that were recently evaluated in a large randomized trial: enalapril, amlodipine, acebutolol, and chlorthalidone. Clinical evaluation, therapy, and monitoring for hypertension are modeled with an incidence-based Markov model. Clinical inputs include agent efficacy, side effects, and compliance with dosing schedules. JNC-recommended clinical and laboratory monitoring schedules are followed for each agent. Switches between classes occur for therapeutic failures. Drug and medical care costs are valued in 1995 US dollars. RESULTS Although patients whose hypertension was initially treated with amlodipine achieved control more readily than patients who were given the other agents, the initial costs to achieve and maintain hypertension control were lowest for chlorthalidone ($641), followed by acebutolol ($920), amlodipine ($946), and enalapril ($948). Maintenance costs were lowest for chlorthalidone. For all agents except chlorthalidone, drug costs were the largest component of overall costs, followed by the costs of office visits, laboratory monitoring, and switching between classes for therapeutic failures. CONCLUSIONS By following JNC guidelines, a slightly higher percentage of patients will achieve hypertension control with a newer class calcium channel blocker (amlodipine) but at a substantially higher cost than with a generic diuretic (chlorthalidone).
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington, Seattle, USA
| | | | | | | |
Collapse
|
48
|
Abstract
OBJECTIVE To determine the incidence of foot ulcers in a large cohort of patients with diabetes, the risk of developing serious complications after diagnosis, and the attributable cost of care compared with that in patients without foot ulcers. RESEARCH DESIGN AND METHODS Retrospective cohort study of patients with diabetes in a large staff-model health maintenance organization from 1993 to 1995. Patients with diabetes were identified by algorithm using administrative, laboratory, and pharmacy records. The data were used to calculate incidence of foot ulcers, risk of osteomyelitis, amputation, and death after diagnosis of foot ulcer, and attributable costs in foot ulcer patients compared with patients without foot ulcers. RESULTS Among 8,905 patients identified with type 1 or type 2 diabetes, 514 developed a foot ulcer over 3 years of observation (cumulative incidence 5.8%). On or after the time of diagnosis, 77 (15%) patients developed osteomyelitis and 80 (15.6%) required amputation. Survival at 3 years was 72% for the foot ulcer patients versus 87% for a group of age- and sex-matched diabetic patients without foot ulcers (P < 0.001). The attributable cost for a 40- to 65-year-old male with a new foot ulcer was $27,987 for the 2 years after diagnosis. CONCLUSIONS The incidence of foot ulcers in this cohort of patients with diabetes was nearly 2.0% per year. For those who developed ulcers, morbidity, mortality, and excess care costs were substantial compared with those for patients without foot ulcers. The results appear to support the value of foot-ulcer prevention programs for patients with diabetes.
Collapse
Affiliation(s)
- S D Ramsey
- Department of Medicine, University of Washington 98195, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
OBJECTIVE To estimate the number of lung volume reduction surgery procedures performed on Medicare enrollees from 1994 to 1996. DESIGN Statistical analysis of national Medicare claims data. PATIENTS All Medicare enrollees with emphysema hating claims records for pulmonary resection procedures from January 1, 1993, through December 31, 1996. MAIN OUTCOME MEASURE Estimated number of lung volume reduction procedures performed per month from July 1994 through December 1996. RESULTS An estimated 1,212 lung volume reduction procedures were performed on Medicare enrollees between July 1994 and December 1995 (95% confidence interval, 1,012 to 1,408). Nearly one half of these procedures were performed in the last 3 months of 1995. At the time Health Care Financing Administration announced that it would suspend reimbursement for the procedure (December 1995), lung volume reduction surgery was being performed in 37 states. The number of claims per month decreased from a peak of 169 in December 1995, to 11 in March 1996. Average Medicare reimbursement per procedure was $31,398. CONCLUSIONS Lung volume reduction surgery for patients increased rapidly following its reintroduction in 1994. The growth of lung volume reduction surgery demonstrates that widespread adoption and utilization of a surgical procedure can occur in the absence of data from controlled clinical trials. Medicare expenditures for lung volume reduction surgery were an estimated $30 million to $50 million. Performing the surgery for all current Medicare patients who meet the appropriate clinical criteria would cost an estimated $1 billion.
Collapse
Affiliation(s)
- H F Huizenga
- Division of General Internal Medicine and Health Services, University of Washington, Veterans Administration Puget Sound Health Care System, Seattle 98108, USA.
| | | | | |
Collapse
|
50
|
Ramsey SD, Luce BR, Deyo R, Franklin G. The limited state of technology assessment for medical devices: facing the issues. Am J Manag Care 1998; 4 Spec No:SP188-99. [PMID: 10185994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Medical devices are an integral part of clinical practice and account for a substantial proportion of the national health budget. Clinical testing and regulation of medical devices, however, is vastly different from and inferior to the testing and regulation of drugs. As managed care organizations begin to exert controls on device use, providers are being caught between the policies of their organizations and the demands of device manufacturers and patients, who want wider access to devices. We outline several reasons for the poor state of medical device evaluations and the dangers of using devices without adequate information, and include the recently developed device assessment and reporting guidelines created by the Task Force on Technology Assessment of Medical Devices.
Collapse
Affiliation(s)
- S D Ramsey
- Center for Cost and Outcomes Research, University of Washington, Seattle, WA 98103, USA.
| | | | | | | |
Collapse
|